130 related articles for article (PubMed ID: 16951353)
1. Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab' conjugates.
Guillaume P; Baumgaertner P; Angelov GS; Speiser D; Luescher IF
J Immunol; 2006 Sep; 177(6):3903-12. PubMed ID: 16951353
[TBL] [Abstract][Full Text] [Related]
2. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
3. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
[TBL] [Abstract][Full Text] [Related]
4. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
[TBL] [Abstract][Full Text] [Related]
5. Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
Schmidt J; Guillaume P; Irving M; Baumgaertner P; Speiser D; Luescher IF
J Biol Chem; 2011 Dec; 286(48):41723-41735. PubMed ID: 21990358
[TBL] [Abstract][Full Text] [Related]
6. High avidity antigen-specific CTL identified by CD8-independent tetramer staining.
Choi EM; Chen JL; Wooldridge L; Salio M; Lissina A; Lissin N; Hermans IF; Silk JD; Mirza F; Palmowski MJ; Dunbar PR; Jakobsen BK; Sewell AK; Cerundolo V
J Immunol; 2003 Nov; 171(10):5116-23. PubMed ID: 14607910
[TBL] [Abstract][Full Text] [Related]
7. An antigen-targeted approach to adoptive transfer therapy of cancer.
Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
[TBL] [Abstract][Full Text] [Related]
8. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
10. Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.
Guillaume P; Baumgaertner P; Neff L; Rufer N; Wettstein P; Speiser DE; Luescher IF
Int J Cancer; 2010 Aug; 127(4):910-23. PubMed ID: 19998338
[TBL] [Abstract][Full Text] [Related]
11. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.
Dunbar PR; Ogg GS; Chen J; Rust N; van der Bruggen P; Cerundolo V
Curr Biol; 1998 Mar; 8(7):413-6. PubMed ID: 9545200
[TBL] [Abstract][Full Text] [Related]
12. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
13. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
Lev A; Novak H; Segal D; Reiter Y
J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface.
Wooldridge L; Hutchinson SL; Choi EM; Lissina A; Jones E; Mirza F; Dunbar PR; Price DA; Cerundolo V; Sewell AK
J Immunol; 2003 Dec; 171(12):6650-60. PubMed ID: 14662868
[TBL] [Abstract][Full Text] [Related]
16. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
17. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
[TBL] [Abstract][Full Text] [Related]
18. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR.
Denkberg G; Cohen CJ; Reiter Y
J Immunol; 2001 Jul; 167(1):270-6. PubMed ID: 11418659
[TBL] [Abstract][Full Text] [Related]
19. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
20. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]